Cite
HARVARD Citation
Martín, M. et al. (2022). Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. European journal of cancer. pp. 12-24. [Online].